Conexeu Sciences Inc. approved a warrant exercise inducement program offering holders of Existing Warrants—outstanding to purchase up to 4,762,780 shares as of October 21, 2026—one new warrant for each Existing Warrant exercised before 4:00 p.m. Reno time on April 30, 2027. The Existing Warrants have a $2.30 per-share exercise price. Each Inducement Warrant costs $0.001 and can be exercised to purchase one share at $3.00 for 24 months from its issuance.
Inducement Warrant shares are subject to a 2,563,389-share cap until stockholder approval, allocated first to exercise. The board also agreed to register for resale on Form S-1 shares certain holders have received or receive upon exercise, excluding shares held or deemed beneficially owned by company affiliates. For certain holders subject to voluntary pooling agreements, covered securities are released on May 21, 2027.
Conexeu Sciences Inc. reported a Rule 506(b) exempt offering of equity units and warrants, listing $1,499,997 USD as both the total amount sold and the total remaining to be sold.
The stated offering-amount calculation uses 499,999 units at $3.00 plus the aggregate exercise price for 499,999 warrants at $3.00; the warrants form part of the units. The first sale was October 15, 2026. Finders' fees were $0 USD.
Conexeu Sciences Inc. (CNXU) supplements its prospectus for 9,481,123 shares of common stock and adds disclosures about recent issuances.
On October 15, 2026, the company issued 1,333,333 units at $3.00 each for gross proceeds of $3,999,999. Each unit includes one share and a warrant to buy one share at $3.00, exercisable for 24 months. It also issued 250,000 special warrants at $3.00 each for gross proceeds of $750,000; they convert automatically into one share and one warrant upon the earlier of receipt of the qualifying British Columbia prospectus or February 16, 2027. Proceeds from these issuances are intended for working capital and general corporate purposes.
A separate subscription for 83,334 units, valued at $250,002, is held in escrow pending stockholder approval; without approval, the securities will not be issued and the funds will be returned. The company also agreed to file a continuous resale registration statement for the private-placement shares and warrant shares by the 35th calendar day after October 15, 2026, excluding affiliate-held shares; late filing would require cash partial liquidated damages equal to 2.0% of a subscriber’s aggregate subscription price.
Conexeu Sciences Inc. issued 1,333,333 Units on October 15, 2026, at $3.00 each for gross proceeds of $3,999,999. Each Unit contains one common share and one warrant to buy one share at $3.00, exercisable for 24 months from issuance. The company also issued 250,000 Special Warrants at $3.00 each for gross proceeds of $750,000; each automatically converts into one share and one warrant upon the earlier of receipt by the British Columbia Securities Commission of the final Canadian prospectus qualifying their distribution in British Columbia or February 16, 2027. The company intends to use the proceeds for working capital and general corporate purposes.
Subscriptions by management and directors for 83,334 Units remain in escrow pending stockholder approval; if approved, $250,002 will be released to the company, and otherwise the funds will be returned. From September 14 through October 15, 2026, Conexeu reported issuing 1,290,000 shares, 1,333,333 Units and 250,000 Special Warrants, which it said collectively exceeded 5% of its issued and outstanding common shares since its last periodic report. Conexeu agreed to file a continuous resale Form S-1 for the shares and Warrant Shares by the 35th calendar day following October 15, 2026, excluding affiliate-held shares.
Conexeu Sciences Inc. (CNXU) director and 10% owner Lynn Sebastian Purcell reported that OnePointTwo Capital Ventures II LLC bought 166,666 common shares on October 15, 2026, through units priced at $3.00 per unit. Each unit included one share and one warrant to purchase one common share at $3.00 per share. After the transactions, the LLC held 3,118,514 common shares and 574,058 warrants.
Conexeu Sciences Inc. reported a Rule 506(b) exempt equity offering with $30,875 sold. That amount represents 6,500 shares at a deemed price of $4.75 per share, issued as payment for consulting services. The first sale was September 23, 2026, and the total remaining to be sold was $0.
Conexeu Sciences Inc. (CNXU) Chief Commercial Officer and director David Robert Bogart exercised 750,000 Performance Warrants on September 25, 2026, acquiring 750,000 common shares at $0.001 per share. His direct common-stock holdings after the transaction were 1,812,500 shares. His reported post-transaction balance was 250,000 Performance Warrants, which will vest and become exercisable upon the issuer submitting a 510(k) application to the U.S. Food and Drug Administration. Separately, 431,250 common shares were held by 0865546 B.C. Ltd., over which Bogart has sole voting and dispositive power.
Conexeu Sciences Inc. (CNXU) director Jeffrey Sharpe filed an amended Schedule 13D reporting updated ownership after warrant exercises. As of September 14, 2026, he beneficially owns 1,500,000 shares of Common Stock, representing 5.2% of the outstanding shares, following the exercise of 500,000 Performance Warrants at an exercise price of $0.001 per share. He also holds 500,000 additional Performance Warrants that remain unvested and will vest only upon the issuer’s submission of a 510(k) application to the U.S. Food and Drug Administration.
Conexeu Sciences Inc. (CNXU) director Jeffrey Nathan Sharpe exercised 500,000 Performance Warrants on September 14, 2026, at an exercise price of $0.001 per share, receiving 500,000 shares of Common Stock and bringing his direct holdings to 1,500,000 shares. The exercised Performance Warrants were granted on June 5, 2025 for services, vesting upon a market capitalization milestone, and were structured with a 5-year term to June 5, 2030. The transaction is disclosed as exempt from Section 16(b) under Rule 16b-6(b), and no Rule 10b5-1 trading plan is reported.
Conexeu Sciences Inc. (CNXU), a Nevada-based biotechnology company, filed a Form D for a new exempt equity offering under Rule 506(b) of Regulation D. The notice reports that the company has sold $252,148 of equity securities, with no remaining amount offered.
The total offering amount reflects 1,667 shares issued at a deemed price of $7.07 per share and 33,500 shares issued at a deemed price of $7.175 per share, all as payment for consulting services rather than for cash. No finders’ fees were paid in connection with this issuance.